

Attorney Docket No.: 6608.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Petersen et al.

Serial No.: 10/701,294

Group Art Unit: To be assigned

Filed: November 4, 2003

Examiner: To be assigned

For: PHARMACEUTICAL COMPOSITION COMPRISING A TISSUE FACTOR
ANTAGONIST AND A BLOOD GLUCOSE REGULATOR

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (18)


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on January 23, 2004

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)



Attorney Docket No.: 6608.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Petersen et al.

Application No.: 10/701,294

Group Art Unit: To be assigned

Filed: November 4, 2003

Examiner: To be assigned

For: PHARMACEUTICAL COMPOSITION COMPRISING A TISSUE FACTOR
ANTAGONIST AND A BLOOD GLUCOSE REGULATOR

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. US Patent No. 5,223,427
2. US Patent No. 6,001,978
3. WO 90/03390 A1
4. WO 92/15686 A1
5. WO 94/27631 A1
6. WO 95/00541 A1
7. WO 96/12800 A1
8. WO 96/18653 A1
9. WO 97/47651 A1
10. WO 99/48878 A1
11. WO 99/51743 A1 and translation of claims
12. WO 01/21661 A1
13. WO 01/85256 A2
14. WO 02/087605 A2
15. WO 02/22776 A2
16. EP 0083391 A2
17. EP 0500800 B1
18. Presta et al., Thrombosis and Haemostasis, Vol. 85, pages 379-389 (2001)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: January 23, 2004

Respectfully submitted,


Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,223,427	6/29/93	Edgington et al.	435	240	
		6,001,978	12/14/99	Edgington et al.	530	391.3	

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 90/03390 A1	4/5/90	PCT				
		WO 92/15686 A1	9/17/92	PCT				
		WO 94/27631 A1	12/8/94	PCT				
		WO 95/00541 A1	1/5/95	PCT				
		WO 96/12800 A1	5/2/96	PCT				
		WO 96/18653 A1	6/20/96	PCT				
		WO 97/47651 A1	12/18/97	PCT				
		WO 99/48878 A1	9/30/99	PCT				

[illegible]

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6608.200-US

Serial No. 10/701,294

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant Petersen et al.

(Use several sheets if necessary)

Filing Date November 4, 2003

Group To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 99/51743 A1	10/14/99	PCT			Claims	
	WO 01/21661 A1	3/29/01	PCT				
	WO 01/85256 A2	11/15/01	PCT				
	WO 02/087605 A2	11/7/02	PCT				
	WO 02/22776 A2	3/21/02	PCT				
	EP 0083391 A2	9/16/82	EPO			Ab- stract	
	EP 0500800 B1	8/10/94	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

